Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN

肾小球疾病 医学 蛋白尿 安慰剂 疾病 免疫学 肾小球肾炎 内科学 临床试验 胃肠病学 还原(数学) 肾病 贝那普利 肾
作者
Fádi Fakhouri,Andrew S. Bomback,Gema Ariceta,Yahsou Delmas,Bradley P. Dixon,Daniel Philip Gale,Larry A. Greenbaum,Seung Hyeok Han,Nicole M. Isbel,Moglie Le Quintrec,Christoph P. B. Licht,Antonio Mastrangelo,Masashi Mizuno,Maria Izabel de Holanda,Matthew Caleb Pickering,Giuseppe Remuzzi,Nicole C. A. J. van de Kar,Marina Vivarelli,Patrick D. Walker,Dean Wallace
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:393 (22): 2210-2220 被引量:64
标识
DOI:10.1056/nejmoa2501510
摘要

BACKGROUND: C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis (MPGN) generally result in glomerular C3 deposition and irreversible kidney damage. The efficacy and safety of pegcetacoplan, a C3 and C3b inhibitor, in persons with C3 glomerulopathy or primary immune-complex MPGN are unclear. METHODS: We conducted a phase 3, double-blind, placebo-controlled trial involving adolescents and adults with C3 glomerulopathy or primary immune-complex MPGN, including those with native kidney disease and those with disease recurrence after transplantation. Patients were randomly assigned in a 1:1 ratio to receive pegcetacoplan or placebo. The primary end point was the log-transformed ratio of the urinary protein-to-creatinine ratio at week 26 as compared with baseline. RESULTS: A total of 124 patients underwent randomization. The change in proteinuria (as measured by the log-transformed ratio to baseline in the urinary protein-to-creatinine ratio) was significantly greater with pegcetacoplan than with placebo (geometric mean of the urinary protein-to-creatinine ratio, -67.2% [95% confidence interval {CI}, -74.9 to -57.2] vs. 2.9% [95% CI, -8.6 to 15.9]). The difference represents a relative reduction of 68.1% (95% CI, 57.3 to 76.2) as compared with placebo. In hierarchical testing of five secondary end points, significantly higher percentages of patients in the pegcetacoplan group than in the placebo group met the composite renal end-point criteria (stabilization of estimated glomerular filtration rate [eGFR] and ≥50% reduction in urinary protein-to-creatinine ratio) (49% vs. 3%) and had at least a 50% reduction in the protein-to-creatinine ratio (60% vs. 5%). Among 69 patients with evaluable kidney-biopsy samples, the change in the activity score of the C3 glomerulopathy histologic index did not differ significantly between the two groups; subsequent end points (decrease in C3 staining and change in eGFR) were not formally tested. Pegcetacoplan was not associated with more adverse events than placebo. No serious infections from encapsulated bacteria occurred; 1 patient receiving pegcetacoplan died from coronavirus disease 2019 pneumonia. No allograft rejection or loss occurred. CONCLUSIONS: Pegcetacoplan resulted in a significantly greater reduction in proteinuria than placebo among patients with C3 glomerulopathy or primary immune-complex MPGN. (Funded by Apellis Pharmaceuticals and Sobi [Swedish Orphan Biovitrum]; VALIANT ClinicalTrials.gov number, NCT05067127.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大力思雁发布了新的文献求助10
1秒前
1秒前
顾矜的应助被mew桑采纳,获得10
1秒前
ewmmel发布了新的文献求助10
1秒前
ding的应助被嘛丝丝采纳,获得10
1秒前
112233cc完成签到,获得积分20
2秒前
於依白完成签到,获得积分10
3秒前
毛毛完成签到 ,获得积分10
4秒前
科研通AI6.2的应助被zd采纳,获得10
4秒前
李健的应助被清晨之风采纳,获得10
5秒前
5秒前
安详忆雪完成签到,获得积分10
5秒前
5秒前
科研通AI6.2的应助被lihui采纳,获得10
6秒前
秋风的应助被lihui采纳,获得10
6秒前
今后的应助被卑微研究生张三采纳,获得20
6秒前
7秒前
8秒前
8秒前
9秒前
9秒前
小小发布了新的文献求助200
9秒前
斯文明杰发布了新的文献求助10
9秒前
10秒前
10秒前
10秒前
晨臆织梦rl完成签到 ,获得积分10
10秒前
10秒前
11秒前
11秒前
xz完成签到 ,获得积分10
11秒前
13秒前
传奇3的应助被Dddxxx采纳,获得10
13秒前
13秒前
13秒前
13秒前
malone发布了新的文献求助10
13秒前
乐乐的应助被任性雪糕采纳,获得10
13秒前
13秒前
malone发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153710
求助须知:如何正确求助?哪些是违规求助? 9550475
关于积分的说明 21698625
捐赠科研通 7742521
什么是DOI,文献DOI怎么找? 3425571
关于科研通互助平台的介绍 2550735
邀请新用户注册赠送积分活动 2469211